wherein

B is cytosine or 5-fluorocytosine,

R is H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, or

Rc is in each case independently H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or a hydroxy protecting group, and wherein said compound is substantially in the form of the (-) enantiomer; and

a chemotherapeutic agent selected from Asparaginase, Bleomycin, Busulfan, Carmustine, Chlorambucil, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Daunorubicin, Doxorubicin, Etoposide, Fludarabine, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Lomustine, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Pentostatin, Procarbazine, 6-Thioguanine, Topotecan, Vinblastine, Vincristine, Dexamethasone, Retinoic acid and Prednisone.—

Please add the following new claims:

- --60. A method according to claim 11, wherein said compound of formula I is (-)-β-L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.
- 61. A method according to claim 22, wherein said compound of formula I is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.

- 62. A composition according to claim 38, wherein said compound of formula I is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.
- 63. A combination according to claim 57, wherein said compound of formula I is (-)-β-L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof, and said chemotherapeutic agent is Doxorubicin.--